摘要
静脉溶栓治疗是急性缺血性脑卒中超早期治疗的首选方法,重组组织型纤溶酶原激活剂(rt-PA)是目前临床上广泛应用的静脉溶栓药物。既往静脉溶栓将80岁以上高龄患者排除在外,现年龄因素不再是应用排除标准。现对高龄缺血性脑卒中患者应用rt-PA静脉溶栓治疗有效性、时间窗、剂量、颅内出血并发症等相关研究进行综述,以对高龄患者应用rt-PA静脉溶栓治疗提供临床参考依据。
Intravenous thrombolysis is the first choice for the ultra early treatment of acute ischemic stroke,and the recombinant tissue plasminogen activator is a widely used intravenous thrombolytic agent.Previous intravenous thrombolysis excluded the elderly patients over 80 years old,but age is no longer an exclusion criterion.The safety,time window,dose and intracranial hemorrhage complications of rt-PA intravenous thrombolysis in elderly patients with ischemic stroke were reviewed to provide clinical reference basis for rt-PA intravenous thrombolysis in elderly patients.
作者
高红玉
刘宏
GAO Hongyu;LIU Hong(Department of Neurology,Neurology Intensive Care Unit,Qingdao University Affiliated Yantai Yuhuangding Hospital,Yantai 264000,China)
出处
《中国实用神经疾病杂志》
2019年第1期98-102,共5页
Chinese Journal of Practical Nervous Diseases